Hyperoxaluria and systemic oxalosis: current therapy and future directions

Bibliography

• DANPURE C, RUMSBY G: Molecular aetiology of primary hyperoxaluria and its implications for clinical management. Expert Rev. Mol. Med. (2004) 2004:1-16.
   Google Scholar
• COCHAT P, DELORAINE A, ROTILY M, OLIVE F, LIPONSKI I, DERIES N: Epidemiology of primary hyperoxaluria type 1. Nephrol. Dial. Transplant. (1995) 10(Suppl. 8):3-7.
   PubMedGoogle Scholar
• MILLINER D, WILSON D, SMITH L: Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int. (2001) 59(1):31-36.
   PubMed Web of Science ®Google Scholar
• MILLINER D, WILSON D, SMITH L: Clinical expression and long-term outcomes of primary hyperoxaluria types 1 and 2. J. Nephrol. (1998) 11(Suppl. 1):56-59.
   Google Scholar
• HOPPE B, LATTA K, VON SCHNAKENBURG C, KEMPER M: Primary hyperoxaluria – the German experience. Am. J. Nephrol. (2005) 25:276-281.
   PubMed Web of Science ®Google Scholar
• HOPPE B, LANGMAN C: A United States survey on diagnosis, treatment, and outcome of primary hyperoxaluria. Pediatr. Nephrol. (2003) 18:986-991.
   PubMed Web of Science ®Google Scholar
• TERRIBILE M, CAPUANO M, MARANGELLA M et al.: Factors increasing the risk for stone formation in adult patients with cystic fibrosis. Nephrol. Dial. Transplant. (2006) 21:1870-1875.
   PubMed Web of Science ®Google Scholar
• JIANG Z, ASPLIN J, ARONSON P et al.: Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat. Genetics (2006) 38(4):474-478.
   PubMed Web of Science ®Google Scholar
• MILLINER D: The primary hyperoxalurias: an algorithm for diagnosis. Am. J. Nephrol. (2005) 25(2):154-160.
   Google Scholar
• RUMSBY G, WILLIAMS E, COULTER-MACKIE M: Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. Kidney Int. (2004) 66:959-963.
   PubMed Web of Science ®Google Scholar
• LEUMANN E, HOPPE B: The primary hyperoxalurias. J. Am. Soc. Nephrol. (2001) 12:1986-1993.
   PubMed Web of Science ®Google Scholar
• TOUSSAINT C: Pyridoxine-responsive PH1: treatment. J. Nephrol. (1998) 11(Suppl. 1):49-50.
   PubMedGoogle Scholar
• MILLINER D, EICKHOLT J, BERGSTRALH I, WILSON D, SMITH L: Results of long-term treatment with orthophosphate and pyridoxine in patients with primary hyperoxaluria. N. Engl. J. Med. (1994) 331(23):1553-1558.
   PubMed Web of Science ®Google Scholar
• BERGER A, SCHAUMBURG H: More on neuropathy from pyridoxine abuse. N. Engl. J. Med. (1984) 311:986-987.
   PubMed Web of Science ®Google Scholar
• VAN WOERDEN C, GROOTHOFF J, WIJBURG F, ANNINK C, WANDERS R, WATERHAM H: Clinical implications of mutation analysis in primary hyperoxaluria Type 1. Kidney Int. (2004) 66(2):746-752.
   PubMed Web of Science ®Google Scholar
• MONICO C, ROSSETTI S, OLSON J, MILLINER D: Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int. (2005) 67(5):1704-1709.
   PubMed Web of Science ®Google Scholar
• MONICO C, OLSON J, MILLINER D: Implications of genotype and enzyme phenotype in pyridoxine response of pateints with Type I primary hyperoxaluria. Am. J. Nephrol. (2005) 25:183-188.
   PubMed Web of Science ®Google Scholar
• LEUMANN E, HOPPE B, NEUHAUS T, BLAU N: Efficacy of oral citrate administration in primary hyperoxaluria. Nephrol. Dial. Transplant. (1995) 10(Suppl. 8):14-16.
   Google Scholar
• RODGERS A, ALLIE-HAMDULAY S, JACKSON G: Therapeutic action of citrate in urolithiasis explained by chemical speciation: increase in pH is the determinant factor. Nephrol. Dial. Transplant. (2006) 21(2):361-369.
   Google Scholar
• ZIMMERMANN D, VOSS S, VON UNRUH G, HESSE A: Importance of magnesium in absorption and excretion of oxalate. Urology Int. (2005) 74(3):262-267.
   PubMed Web of Science ®Google Scholar
• MASSEY L: Magnesium therapy for nephrolithiasis. Magnes. Res. (2005) 18(2):123-126.
   Google Scholar
• PRAGASAM V, KALAISELVI P, SUMITRA K, SRINIVASAN S, VARALAKSHMI P: Oral l-arginine supplementation ameliorates urinary risk factors and kinetic modulation of Tamm-Horsfall glycoprotein in experimental hyperoxaluric rats. Clin. Chim. Acta. (2005) 360(1-2):141-150.
   Web of Science ®Google Scholar
• LEUMANN E, HOPPE B, NEUHAUS T: Management of primary hyperoxaluria: efficacy of oral citrate administration. Pediatr. Nephrol. (1993) 7(2):207-211.
   PubMed Web of Science ®Google Scholar
• HOLMES R, ASSIMOS D, WILSON D, MILLINER D: L-2-oxothiazolidine-4-carboxylate in the treatment of primary hyperoxaluria Type 1. BJU Int. (2001) 88:858-862.
   PubMed Web of Science ®Google Scholar
• CHETYRKIN S, KIM D, BELMONT J, SCEINMAN J, HUDSON B, VOZIYAN P: Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int. (2005) 67(1):53-60.
   PubMedGoogle Scholar
• MARANGELLA M, COSSEDDU D, PETRARULO M, VITALE C, LINARI F: Thresholds of serum calcium oxalate supersaturation in relation to renal function in patients with or without primary hyperoxaluria. Nephrol. Dial. Transplant. (1993) 8:1333-1337.
   Google Scholar
• FRANSSEN C: Oxalate clearance by haemodialysis-a comparison of seven dialysers. Nephrol. Dial. Transplant. (2005) 20:1916-1921.
   Google Scholar
• DIAZ C, CATALINAS F, DE ALVARO F, TORRE A, SANCHEZ C, COSTERO O: Long daily hemodialysis sessions correct systemic complications of oxalosis prior to combined liver-kidney transplantaion: case report. Therap. Apher. Dial. (2004) 8(1):52-55.
   Google Scholar
• HOPPE B, GRAF D, OFFNER G et al.: Oxalate elimination via hemodialysis or peritoneal dialysis in children with chronic renal failure. Pediatr. Nephrol. (1996) 10(4):488-492.
   PubMed Web of Science ®Google Scholar
• SABORIO P, SCHEINMAN J: Transplantation for primary hyperoxaluria in the United States. Kidney Int. (1999) 56:1094-1100.
   PubMed Web of Science ®Google Scholar
• JAMIESON N: A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 Transplant Registry Experience 1984 – 2004. Am. J. Nephrol. (2005) 25:282-289.
   PubMed Web of Science ®Google Scholar
• COCHAT P, GAULIER J, KOCH NOGUEIRA P et al.: Combined liver-kidney transplantation in primary hyperoxaluria Type 1. Eur. J. Pediatr. (1999) 158(Suppl. 2):S75-S80.
   Google Scholar
• MONICO C, MILLINER D: Combined liver-kidney and kidney-alone transplantation in primary hyperoxaluria. Liver Transpl. (2001) 7(11):954-963.
   PubMed Web of Science ®Google Scholar
• CIBRIK D, KAPLAN B, ARNDORFER J, MIER-KRIESCHE H: Renal allograft survival in patients with oxalosis. Transplantation (2002) 74:707-710.
   PubMedGoogle Scholar
• DETRY O, HONORE P, DEROOVER A et al.: Reversal of oxalosis cardiomyopathy after combined liver and kidney transplantation. Transpl. Int. (2002) 15(1):50-52.
   Google Scholar
• GAGNADOUX M, LACAILLE F, NIAUDET P et al.: Long term results of liver-kidney transplantation in children with primary hyperoxaluria. Pediatr. Nephrol. (2001) 16:946-950.
   Web of Science ®Google Scholar
• SHAPIRO R, WEISMANN I, MANDEL H et al.: Primary hyperoxaluria type 1: improved outcome with timely liver transplantation: a single-center report of 36 children. Transplantation (2001) 72(3):428-432.
   Google Scholar
• ELLIS S, HULTON S, MCKIERNAN P, DEVILLE DE GOYET J, KELLY D: Combined liver-kidney transplantation for primary hyperoxaluria type 1 in young children. Nephrol. Dial. Transplant. (2001) 16:348-354.
   PubMed Web of Science ®Google Scholar
• ROGERS J, BUENO J, SHAPIRO R et al.: Results of simultaneous and sequential pediatric liver and kidney transplantation. Transplantation. (2001) 72(10):1666-1670.
   Google Scholar
• SATO S, FUCHINOUE S, KIMIKAWA M et al.: Sequential liver-kidney transplantation from a living-related donor in primary hyperoxaluria Type 1 (oxalosis). Transplant. Proc. (2003) 35:373-374.
   Google Scholar
• ASTARCIOGLU I, KARADEMIR S, GULAY H et al.: Primary hyperoxaluria: simultaneous combined liver and kideny transplantation from a living related donor. Liver Transpl. (2003) 9(4):433-436
   Google Scholar
• ONACA N, SANCHEZ E, MELTON L et al.: Cadaveric orthotopic auxiliary split liver transplantation and kidney transplantation: an alternative for type 1 primary hyperoxaluria. Transplantation (2005) 80:421-424.
   Google Scholar
• NOLKEMPER D, KEMPER M, BURDELSKI M et al.: Long-term results of pre-emptive liver transplantation in primary hyperoxaluria Type 1. Pediatr Transplant. (2000) 4(3):177-181.
   Google Scholar
• COCHAT P, KOCH NOGUEIRA P, MAHMOUD M, JAMIESON N, SCHEINMAN J, ROLLAND M: Primary hyperoxaluria in infants: medical, ethical, and economic issues. J. Pediatr. (1999) 135(6):746-750.
   Google Scholar
• MILLAN M, BERQUIST W, SO S et al.: One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation (2003) 76(10):1458-1463.
   PubMed Web of Science ®Google Scholar
• PAK C, HELLER H, PEARLE M, ODVINA C, POINDEXTER J, PETERSON R: Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary-pharmacological interventions. J. Urol. (2003) 169:465-469.
   PubMed Web of Science ®Google Scholar
• CAMPIERI C, CAMPIERI M, BERTUZZI V et al.: Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int. (2001) 60:1097-1105.
   PubMed Web of Science ®Google Scholar
• SIDHU H, ALLISON M, CHOW J, CLARK A, PECK A: Rapid reversal of hyperoxaluria in a rat model after probiotic administration of oxalobacter formigenes. J. Urol.ogy. (2001) 166:1487-1491.
   PubMed Web of Science ®Google Scholar
• LIESKE J, GOLDFARB D, DESIMONE C, REGNIER C: Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. (2005) 68:1244-1249.
   PubMed Web of Science ®Google Scholar
• HATCH M, CORNELIUS J, ALLISON M, SIDHU H, PECK A, FREEL R: Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. (2006) 69(4):691-698.
   PubMed Web of Science ®Google Scholar
• BORGHI L, MESCHI T, GUERRA A, NOVARINI A: Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J. Cardiovasc. Pharmacol. (1993) 22(Suppl. 6):78-86.
   PubMed Web of Science ®Google Scholar
• MASSEY L, LIEBMAN M, KYNAST-GALES S: Ascorbate increases human oxaluria and kidney stone risk. J. Nutr. (2005) 135(7):1673-1677.
   PubMed Web of Science ®Google Scholar
• JAEGER P, PORTMANN L, JACQUET A, BURCKHARDT P: Pyridoxine can normalize oxaluria in idiopathic renal lithiasis. Journal Suisse de Medecine (1986) 116(50):1783-1786.
   Google Scholar
• LUMB M, BIRDSEY G, DANPURE C: Correction of an enzyme trafficking defect in hereditary kidney stone disease in vitro. Biochem. J. (2003) 374(Pt 1):79-87.
   PubMedGoogle Scholar
• SANTANA A, SALIDO E, TORRES A, SHAPIRO L: Primary hyperoxaluria Type 1 in the Canary Islands: a conformational disease due to 1244T mutation in the P11L-containing alanine:glyoxylate aminotransferase. Proc. Natl Acad. Sci. USA (2003) 100(12):7277-7282.
   PubMed Web of Science ®Google Scholar
• ZHANG X, ROE S, HOU Y et al.: Crystal structure of alanine:glyoxylate aminotransferase and the relationship between genotype and enzymatic phenotype in primary hyperoxaluria type 1. J. Mol. Biol. (2003) 331:643-652.
   PubMed Web of Science ®Google Scholar
• SARICA K, ERBAGCI A, YAGCI F, BAKIR K, ERTURHAN S, UCAK R: Limitations of apoptotic changes in renal tubular cell injury induced by hyperoxaluria. Urol. Res. (2004) 32:271-277.
   Google Scholar
• KNIGHT J, HOLMES R: Mitochondrial hydroxyproline metabolism: implications for primary hyperoxaluria. Am. J. Nephrol. (2005) 25:171-175.
   Google Scholar
• GUHA C, YAMANOUCHI K, ROY-CHOWDHURY J et al.: Feasibility of hepatocyte transplantation-based therapies for primary hyperoxaluria. Am. J. Nephrol. (2005) 25:161-170.
   PubMedGoogle Scholar
• KOUL S, JOHNSON T, PRAMANIK S, KOUL H: Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1). Am. J. Nephrol. (2005) 25:176-182.
   Google Scholar